Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/IIa Clinical Trial Evaluating the Safety and Efficacy of IMC001 in Patients With Advanced Epithelial Solid Tumors.

NCT07644403 is registered in ClinicalTrials.gov with Suzhou Immunofoco Biotechnology Co., Ltd as lead sponsor.

NCT NCT07644403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07644403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/IIa Clinical Trial Evaluating the Safety and Efficacy of IMC001 in Patients With Advanced Epithelial Solid Tumors.
Lead sponsor
Suzhou Immunofoco Biotechnology Co., Ltd
Phase
Phase 1/2
Overall status
Enrolling by invitation
Start date
March 5, 2026
Completion date
December 31, 2027
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial cancer patients